Andrew Harkin is a Professor in Pharmacology at the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin. He is a graduate of NUI Galway (BSc., PhD), and prior to joining Trinity College, held a lecturing post in the School of Pharmacy, University College Cork. Over the course of his research career, he has worked in the Department of Psychiatry and Human Behaviour at the University of Mississippi Medical Centre, Safety Pharmacology Laboratories at H. Lundbeck A/S Valby, Copenhagen, and has held post-doctoral research fellowships funded by the Higher Education Authority (Programme for Research in Third Level Institutions) and the Health Research Board of Ireland. He leads the Neuropsychopharmacology Research Group at Trinity College Institute of Neuroscience (TCIN). His group collaborates with a variety of academic and industrial partners on fundamental and clinical projects. His current research interests include bi-directional nervous system immune interactions, the role of stress and inflammation in the pathogenesis of mental illness, the potential of anti-inflammatory agents in treating neurological and psychiatric disorders, targeting glutamate neuronal transmission in neuropsychiatric disorders, and safety pharmacology of recreational drugs.
Andrew Harkin is a Professor in Pharmacology at the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin. He is a graduate of NUI Galway (BSc., PhD), and prior to joining Trinity College, held a lecturing post in the School of Pharmacy, University College Cork. Over the course of his research career, he has worked in the Department of Psychiatry and Human Behaviour at the University of Mississippi Medical Centre, Safety Pharmacology Laboratories at H. Lundbeck A/S Valby, Copenhagen, and has held post-doctoral research fellowships funded by the Higher Education Authority (Programme for Research in Third Level Institutions) and the Health Research Board of Ireland. He leads the Neuropsychopharmacology Research Group at Trinity College Institute of Neuroscience (TCIN). His group collaborates with a variety of academic and industrial partners on fundamental and clinical projects. His current research interests include bi-directional nervous system immune interactions, the role of stress and inflammation in the pathogenesis of mental illness, the potential of anti-inflammatory agents in treating neurological and psychiatric disorders, targeting glutamate neuronal transmission in neuropsychiatric disorders, and safety pharmacology of recreational drugs.